SFPIA
RIGL icon

Stevens First Principles Investment Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$7K – 245
2014
Q2 		$7K Sell
200
-300
-60% -$10.2K ﹤0.01% 194
2014
Q1 		$19K Buy
+500
New +$17.8K 0.01% 162

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stevens First Principles Investment Advisors's RIGL Position: Q3 2014 in Review

Stevens First Principles Investment Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2014, closing a stake of 200 shares — an estimated $7K sold.

Stevens First Principles Investment Advisors first reported a position in RIGL in Q1 2014 and held it in 2 quarters. The position peaked at $19K in Q1 2014. 104 funds tracked by Wall St. Rank hold RIGL as of Q3 2014.

  • Stevens First Principles Investment Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 200 Rigel Pharmaceuticals shares in Q3 2014, an estimated $7K.
  • Stevens First Principles Investment Advisors first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's Rigel Pharmaceuticals position peaked at $19K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2014.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2014, filed 10 Nov 2014.